123 related articles for article (PubMed ID: 38153178)
1. Clinical, histological, and molecular differences in melanoma due to different TERT promoter mutations subtypes. A retrospective cross-sectional study in 684 melanoma patients.
Manrique-Silva E; David ME; Maider AM; García-Casado Z; Moro R; Requena C; Través V; Virós A; Kumar R; Nagore E
Pigment Cell Melanoma Res; 2024 May; 37(3):343-351. PubMed ID: 38153178
[TBL] [Abstract][Full Text] [Related]
2. Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.
Thomas NE; Edmiston SN; Tsai YS; Parker JS; Googe PB; Busam KJ; Scott GA; Zedek DC; Parrish EA; Hao H; Slater NA; Pearlstein MV; Frank JS; Kuan PF; Ollila DW; Conway K
Am J Dermatopathol; 2019 Apr; 41(4):264-272. PubMed ID: 30211730
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Griewank KG; Murali R; Puig-Butille JA; Schilling B; Livingstone E; Potrony M; Carrera C; Schimming T; Möller I; Schwamborn M; Sucker A; Hillen U; Badenas C; Malvehy J; Zimmer L; Scherag A; Puig S; Schadendorf D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25217772
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutation subtypes and survival in stage I and II melanoma patients.
Andrés-Lencina JJ; Rachakonda S; García-Casado Z; Srinivas N; Skorokhod A; Requena C; Soriano V; Kumar R; Nagore E
Int J Cancer; 2019 Mar; 144(5):1027-1036. PubMed ID: 30070694
[TBL] [Abstract][Full Text] [Related]
5. TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors.
Chang GA; Wiggins JM; Corless BC; Syeda MM; Tadepalli JS; Blake S; Fleming N; Darvishian F; Pavlick A; Berman R; Shapiro R; Shao Y; Karlin-Neumann G; Spittle C; Osman I; Polsky D
J Invest Dermatol; 2020 Aug; 140(8):1609-1618.e7. PubMed ID: 32087194
[TBL] [Abstract][Full Text] [Related]
6. Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients.
Roh MR; Park KH; Chung KY; Shin SJ; Rha SY; Tsao H
Am J Cancer Res; 2017; 7(1):134-138. PubMed ID: 28123854
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutation is uncommon in acral lentiginous melanoma.
Liau JY; Tsai JH; Jeng YM; Chu CY; Kuo KT; Liang CW
J Cutan Pathol; 2014 Jun; 41(6):504-8. PubMed ID: 24588324
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma.
Griewank KG; Murali R; Schilling B; Schimming T; Möller I; Moll I; Schwamborn M; Sucker A; Zimmer L; Schadendorf D; Hillen U
PLoS One; 2013; 8(11):e80354. PubMed ID: 24260374
[TBL] [Abstract][Full Text] [Related]
9. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
Macerola E; Loggini B; Giannini R; Garavello G; Giordano M; Proietti A; Niccoli C; Basolo F; Fontanini G
Virchows Arch; 2015 Aug; 467(2):177-84. PubMed ID: 26055532
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation.
Pópulo H; Boaventura P; Vinagre J; Batista R; Mendes A; Caldas R; Pardal J; Azevedo F; Honavar M; Guimarães I; Manuel Lopes J; Sobrinho-Simões M; Soares P
J Invest Dermatol; 2014 Aug; 134(8):2251-2257. PubMed ID: 24691053
[TBL] [Abstract][Full Text] [Related]
11. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
12. Frequency of telomerase reverse transcripter promoter mutations in desmoplastic melanoma subtypes: analyses of 76 cases.
Yang S; Leone D; Frydenlund N; Hoang M; Deng A; Hernandez-Perez M; Biswas A; Singh R; Yaar R; Mahalingam M
Melanoma Res; 2016 Aug; 26(4):361-6. PubMed ID: 27244099
[TBL] [Abstract][Full Text] [Related]
13. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.
Vazquez Vde L; Vicente AL; Carloni A; Berardinelli G; Soares P; Scapulatempo C; Martinho O; Reis RM
Melanoma Res; 2016 Apr; 26(2):93-9. PubMed ID: 26709572
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutations and prognosis in solitary fibrous tumor.
Bahrami A; Lee S; Schaefer IM; Boland JM; Patton KT; Pounds S; Fletcher CD
Mod Pathol; 2016 Dec; 29(12):1511-1522. PubMed ID: 27562490
[TBL] [Abstract][Full Text] [Related]
15. Melanomas of unknown primary frequently harbor TERT-promoter mutations.
Egberts F; Krüger S; Behrens HM; Bergner I; Papaspyrou G; Werner JA; Alkatout I; Haag J; Hauschild A; Röcken C
Melanoma Res; 2014 Apr; 24(2):131-6. PubMed ID: 24463461
[TBL] [Abstract][Full Text] [Related]
16.
Hafezi F; Jaxel L; Lemaire M; Turner JD; Perez-Bercoff D
Biomedicines; 2021 Nov; 9(12):. PubMed ID: 34944589
[No Abstract] [Full Text] [Related]
17. Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma.
de Unamuno Bustos B; Murria Estal R; Pérez Simó G; Simarro Farinos J; Pujol Marco C; Navarro Mira M; Alegre de Miquel V; Ballester Sánchez R; Sabater Marco V; Llavador Ros M; Palanca Suela S; Botella Estrada R
Br J Dermatol; 2018 Aug; 179(2):394-404. PubMed ID: 29278418
[TBL] [Abstract][Full Text] [Related]
18. TERT Promoter Mutations and Telomerase in Melanoma.
Guo Y; Chen Y; Zhang L; Ma L; Jiang K; Yao G; Zhu L
J Oncol; 2022; 2022():6300329. PubMed ID: 35903534
[TBL] [Abstract][Full Text] [Related]
19. Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients.
Manrique-Silva E; Rachakonda S; Millán-Esteban D; García-Casado Z; Requena C; Través V; Kumar R; Nagore E
Br J Dermatol; 2021 Mar; 184(3):504-513. PubMed ID: 32506424
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutation subtypes in 20 in-situ melanomas.
Manrique-Silva E; Reyes-Garcia D; Traves V; Rachakonda S; Requena C; Kumar R; Nagore E
Melanoma Res; 2019 Jun; 29(3):347-348. PubMed ID: 31022060
[No Abstract] [Full Text] [Related]
[Next] [New Search]
